

## Supporting Information For

# Facile Solid-Phase Construction of Indole Derivatives Based on a Traceless, Activating Sulfonyl Linker

Han-Cheng Zhang,\* Hong Ye,<sup>1</sup> Alessandro F. Moretto, Kimberly K. Brumfield, and Bruce E. Maryanoff

Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477 USA

Characterization data for the compounds in **Table 2**:

**Entry 1 (X = H, R = Ph):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.76 (s, 1 H), 7.05 (t, J = 7.5 Hz, 1 H), 7.13 (t, J = 7.5 Hz, 1 H), 7.23 (m, 1 H), 7.37 (m, 3 H), 7.58 (m, 3 H); CI-MS m/z 194 (MH<sup>+</sup>).

**Entry 2 (X = H, R = 4-Me-C<sub>6</sub>H<sub>4</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.39 (s, 3 H), 6.78 (s, 1 H), 7.11 (t, J = 7.7 Hz, 1 H), 7.18 (t, J = 7.7 Hz, 1 H), 7.24 (d, J = 8.0 Hz, 2 H), 7.38 (d, J = 7.9 Hz, 1 H), 7.55 (d, J = 8.0 Hz, 2 H), 7.61 (d, J = 7.7 Hz, 1 H); CI-MS m/z 208 (MH<sup>+</sup>).

**Entry 3 (X = H, R = 4-F-C<sub>6</sub>H<sub>4</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.76 (d, J = 1.5 Hz, 1 H), 7.16 (m, 4 H), 7.40 (d, J = 8.2 Hz, 1 H), 7.63 (m, 3 H); CI-MS m/z 212 (MH<sup>+</sup>).

**Entry 4 (X = H, R = 4-MeO-C<sub>6</sub>H<sub>4</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.86 (s, 3 H), 6.71 (d, J = 1.2 Hz, 1 H), 6.98 (d, J = 8.7 Hz, 2 H), 7.10 (t, J = 7.6 Hz, 1 H), 7.17 (t, J = 7.4 Hz, 1 H), 7.39 (d, J = 7.9 Hz, 1 H), 7.60, (m, 3 H); CI-MS m/z 224 (MH<sup>+</sup>); FAB-HRMS calcd for C<sub>15</sub>H<sub>13</sub>NO 223.0997, found 223.0991.

**Entry 5 (X = H, R = Bu):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.95-1.04 (m, 3 H), 1.36-1.49 (m, 2 H), 1.61-1.71 (m, 2 H), 2.77 (t, J = 7.5 Hz, 2 H), 6.23 (s, 1 H), 7.03-7.12 (m, 2 H), 7.31 (d, J = 7.8 Hz, 1 H), 7.52 (d, J = 7.2 Hz, 1 H); CI-MS m/z 174 (MH<sup>+</sup>).

**Entry 6 (X = H, R = MeOCH<sub>2</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.37 (s, 3 H), 4.62 (s, 2 H), 6.43 (d, J = 1.0 Hz, 1 H), 7.09 (t, J = 6.9 Hz, 1 H), 7.17 (t, J = 6.9 Hz, 1 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.58 (d, J = 7.6 Hz, 1 H); CI-MS m/z 162 (MH<sup>+</sup>).

**Entry 7 [X = H, R = HOCH<sub>2</sub>CH<sub>2</sub> and CH<sub>2</sub>=CH (1:1 ratio)]:** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.05 (t, J = 5.7 Hz, 2 H), 4.00 (t, J = 5.8 Hz, 2 H), 5.30 (d, J = 11.2 Hz, 1 H), 5.57 (d, J = 17.8 Hz, 1 H), 6.31 (s, 1 H),

6.52 (s, 1 H), 6.76 (dd,  $J$  = 11.2, 17.8 Hz, 1 H), 7.07-7.22 (m, 4 H), 7.35 (d,  $J$  = 8.0 Hz, 2 H), 7.57 (m, 2 H).

**Entry 8 [X = H, R = (EtO)<sub>2</sub>CH]:** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.28 (t,  $J$  = 7.0 Hz, 6 H), 3.56-3.76 (m, 4 H), 5.78 (s, 1 H), 6.54 (s, 1 H), 7.12 (t,  $J$  = 7.5 Hz, 1 H), 7.20 (t,  $J$  = 7.5 Hz, 1 H), 7.39 (d,  $J$  = 8.0 Hz, 1 H), 7.62 (d,  $J$  = 7.7 Hz, 1 H).

**Entry 9 (X = 6-F, R = PhSCH<sub>2</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.24 (s, 2 H), 6.30 (s, 1 H), 6.84 (dt,  $J$  = 9.2, 2.3 Hz, 1 H), 6.98 (d,  $J$  = 9.6 Hz, 1 H), 7.25 (m, 5 H), 7.40 (dd,  $J$  = 8.6, 5.3 Hz, 1 H); CI-MS *m/z* 258 (MH<sup>+</sup>).

**Entry 10 (X = 6-F, R = 6-MeO-2-naphthyl):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.95 (s, 3 H), 6.86-6.93 (m, 2 H), 7.09-7.21 (m, 3 H), 7.54 (dd,  $J$  = 5.3, 8.5 Hz, 1 H), 7.74-7.81 (m, 3 H), 7.96 (s, 1 H); CI-MS *m/z* 292 (MH<sup>+</sup>); FAB-HRMS calcd for C<sub>19</sub>H<sub>14</sub>FNO + H<sup>+</sup> 292.1138, found 292.1127.

**Entry 11 (X = 6-MeO, R = 4-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.88 (s, 3 H), 6.83 (d,  $J$  = 8.7 Hz, 1 H), 6.90 (s, 1 H), 6.97 (s, 1 H), 7.53 (d,  $J$  = 8.7 Hz, 1 H), 7.73 (d,  $J$  = 9.0 Hz, 2 H), 8.27 (d,  $J$  = 8.9 Hz, 2 H); CI-MS *m/z* 269 (MH<sup>+</sup>).

**Entry 12 (X = 6-MeO, R = 4-Me-C<sub>6</sub>H<sub>4</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.37 (s, 3 H), 3.84 (s, 3 H), 6.70 (d,  $J$  = 1.2 Hz, 1 H), 6.78 (dd,  $J$  = 2.2, 8.6 Hz, 1 H), 6.87 (d,  $J$  = 1.7 Hz, 1 H), 7.23 (m, 2 H), 7.48 (m, 3 H); CI-MS *m/z* 238 (MH<sup>+</sup>); FAB-HRMS calcd for C<sub>16</sub>H<sub>15</sub>NO 237.1154, found 237.1157.

**Entry 13 (X = 6-MeO, R= 6-MeO-2-naphthyl):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.88 (s, 3 H), 3.94 (s, 3 H), 6.79-7.19 (m, 5 H), 7.50-7.77 (m, 4 H), 7.93 (s, 1 H); CI-MS *m/z* 304 (MH<sup>+</sup>).

**Entry 14 (X = 6-MeO, R= MeOCH<sub>2</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.33 (s, 3 H), 3.84 (s, 3 H), 4.63 (s, 2 H), 6.34 (s, 1 H), 6.74 (dd,  $J$  = 2.2, 8.6 Hz, 1 H), 6.82 (d,  $J$  = 2.0 Hz, 1 H), 7.42 (d,  $J$  = 8.6 Hz, 1 H); CI-MS *m/z* 192 (MH<sup>+</sup>).

**Entry 15 (X = 5-CO<sub>2</sub>Me, R = Bu):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.96 (t,  $J$  = 7.2 Hz, 3 H), 1.39-1.46 (m, 2 H), 1.69-1.74 (m, 2 H), 2.77 (t,  $J$  = 7.3 Hz, 2 H), 3.92 (s, 3 H), 6.32 (s, 1 H), 7.29 (d,  $J$  = 8.4 Hz, 1 H), 7.82 (d,  $J$  = 8.3 Hz, 1 H), 8.28 (s, 1 H); CI-MS *m/z* 232 (MH<sup>+</sup>).

**Entry 16 (X = 5-CO<sub>2</sub>Me, R = 2-pyridyl):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.94 (s, 3 H), 7.10 (s, 1 H), 7.22, (t, J = 6.2 Hz, 1 H), 7.43 (d, J = 8.6 Hz, 1 H), 7.75 (t, J = 7.7 Hz, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.92 (dd, J = 8.6, 1.5 Hz, 1 H), 8.42 (s, 1 H), 8.59 (d, J = 4.8 Hz, 1 H); CI-MS *m/z* 253 (MH<sup>+</sup>).

**Entry 17 (X = 5-CO<sub>2</sub>Me, R = PhSCH<sub>2</sub>):** <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.91 (s, 3 H), 4.26 (s, 2 H), 6.41 (s, 1 H), 7.22-7.32 (m, 5 H), 7.44 (d, J = 8.2 Hz, 1 H), 7.86 (d, J = 8.6 Hz, 1 H), 8.27 (s, 1 H); CI-MS *m/z* 298 (MH<sup>+</sup>); FAB-HRMS calcd for C<sub>17</sub>H<sub>15</sub>NO<sub>2</sub>S 297.0824, found 297.0832.